Prana Biotechnology Limited (ADR)(NASDAQ:PRAN) stock declined on Monday following negative comments from Summer Street. Analyst Bart Classen said he was not impressed with PBT2 data. “We recently held a conference call on Prana Biotechnology’s (PRAN) PBT2, a treatment for Alzheimer’s and Huntington’s diseases. We are not enthusiastic about the drug’s proposed mechanism, allowing zinc and copper ions into the cell, because there is only a limited amount of ions that can enter the cell before they would precipitate and cause toxic deposits. We are not impressed with the data to date supporting PBT2 as a treatment for Alzheimer’s disease,” said Classen. Prana Biotechnology Limited (ADR)(NASDAQ:PRAN) shares closed at $9.14 on last trade day, by losing -7.86%. Stock 52 week range is $2.06 – $13.29. Company’s market capitalization is $372.37 billion.
U.S. Food and Drug Administration reviewers are divided on whether an intravenous blood clot preventer developed by The Medicines Company (NASDAQ:MDCO) should be approved, news that sent the company’s stock down more than 7 percent on Monday. Medical Team Leader Dr. Thomas Marciniak recommended the drug, cangrelor, not be approved, saying data did not show the product was as good as or superior to a rival drug. Another reviewer, Dr. Fred Senatore, recommended the drug be approved. The Medicines Company (NASDAQ:MDCO) stock decreased -5.26% and finished the last session at $32.42. The EPS of the stock remained 0.59. Company’s market capitalization is $2.07 billion.
Changyou.com Ltd (NASDAQ:CYOU) issued an update on its first quarter earnings guidance on Monday morning. The company provided earnings per share guidance of ($0.42)-($0.30) for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.04, AnalystRatings.Net reports. The company issued revenue guidance of $174-180 million, compared to the consensus revenue estimate of $199.69 million. Changyou.Com Ltd (ADR) (NASDAQ:CYOU) stock opened at $26.15 in last trading session and closed at $26.74. The 52 week range of the stock is $25.00 – $41.64 and the day range was $25.00 – $27.38.